CAMP Latest Press Releases

-- October 27, 2026 --

CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union Globe Newswire 8:00 AM

-- October 14, 2026 --

CAMP4 to Participate in Chardan's 10th Annual Healthcare Conference Globe Newswire 8:00 AM

-- September 10, 2026 --

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder Globe Newswire 7:33 AM

-- September 8, 2026 --

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026 Globe Newswire 4:05 PM

-- September 1, 2026 --

CAMP4 to Participate in Upcoming Investor Conferences Globe Newswire 4:05 PM

-- August 13, 2026 --

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights Globe Newswire 4:05 PM

-- August 4, 2026 --

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement Globe Newswire 7:00 AM

-- July 27, 2026 --

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder Globe Newswire 7:00 AM

-- July 17, 2026 --

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- July 1, 2026 --

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors Globe Newswire 7:00 AM

-- June 19, 2026 --

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

Market Data Delayed 15 Minutes